Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer.
Gori S, Colozza M, Mosconi AM, Franceschi E, Basurto C, Cherubini R, Sidoni A, Rulli A, Bisacci C, De Angelis V, Crinò L, Tonato M. Gori S, et al. Among authors: cherubini r. Br J Cancer. 2004 Jan 12;90(1):36-40. doi: 10.1038/sj.bjc.6601485. Br J Cancer. 2004. PMID: 14710203 Free PMC article. Clinical Trial.
HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results.
Colozza M, Sidoni A, Mosconi AM, Cavaliere A, Bisagni G, Gori S, De Angelis V, Frassoldati A, Cherubini R, Bian AR, Rodino C, Mazzocchi B, Mihailova Z, Bucciarelli E, Tonato M; Italian Oncology Group for Clincal Research. Colozza M, et al. Among authors: cherubini r. Clin Breast Cancer. 2005 Aug;6(3):253-9. doi: 10.3816/cbc.2005.n.028. Clin Breast Cancer. 2005. PMID: 16137437
Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients.
Ludovini V, Sidoni A, Pistola L, Bellezza G, De Angelis V, Gori S, Mosconi AM, Bisagni G, Cherubini R, Bian AR, Rodinò C, Sabbatini R, Mazzocchi B, Bucciarelli E, Tonato M, Colozza M. Ludovini V, et al. Among authors: cherubini r. Breast Cancer Res Treat. 2003 Sep;81(2):159-68. doi: 10.1023/a:1025755717912. Breast Cancer Res Treat. 2003. PMID: 14572158
Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.
Zeuli M, Di Costanzo E, Sdrobolini A, Gasperoni S, Paoloni FP, Carpi A, Moscetti L, Cherubini R, Cognetti F; Gruppo Oncologico Italiano per la Ricerca Clinica (GOIRC); Gruppo Oncologico Laziale (GOL). Zeuli M, et al. Among authors: cherubini r. Ann Oncol. 2001 Dec;12(12):1737-41. doi: 10.1023/a:1013562914125. Ann Oncol. 2001. PMID: 11843252 Free article. Clinical Trial.
Interphase Cytogenetic Analysis of G0 Lymphocytes Exposed to α-Particles, C-Ions, and Protons Reveals their Enhanced Effectiveness for Localized Chromosome Shattering-A Critical Risk for Chromothripsis.
Pantelias A, Zafiropoulos D, Cherubini R, Sarchiapone L, De Nadal V, Pantelias GE, Georgakilas AG, Terzoudi GI. Pantelias A, et al. Among authors: cherubini r. Cancers (Basel). 2020 Aug 19;12(9):2336. doi: 10.3390/cancers12092336. Cancers (Basel). 2020. PMID: 32825012 Free PMC article.
SEVENTEENTH INTERNATIONAL SYMPOSIUM ON MICRODOSIMETRY.
Cherubini R, Cucinotta FA, O'Neill P. Cherubini R, et al. Radiat Prot Dosimetry. 2019 May 1;183(1-2):1-2. doi: 10.1093/rpd/ncz030. Radiat Prot Dosimetry. 2019. PMID: 30855069 No abstract available.
THE RADIOBIOLOGICAL PLATFORM AT ARRONAX.
Koumeir C, De Nadal V, Cherubini R, Cherel M, Garrido E, Gouard S, Guertin A, Haddad F, Métivier V, Michel N, Poirier F, Servagent N, Sounalet T, Varmenot N. Koumeir C, et al. Among authors: cherubini r. Radiat Prot Dosimetry. 2019 May 1;183(1-2):270-273. doi: 10.1093/rpd/ncy301. Radiat Prot Dosimetry. 2019. PMID: 30668799
TOWARDS THE USE OF NANODOSIMETRY TO PREDICT CELL SURVIVAL.
Selva A, De Nadal V, Cherubini R, Colautti P, Conte V. Selva A, et al. Among authors: cherubini r. Radiat Prot Dosimetry. 2019 May 1;183(1-2):192-196. doi: 10.1093/rpd/ncy274. Radiat Prot Dosimetry. 2019. PMID: 30566675
76 results